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The human IGF-I gene has six exons, four of which are
alternatively spliced. Variations in splicing involving exon
5 may occur, depending on the tissue type and hormonal
environment. To study the regulation of splicing to IGF-I
exon 5, we established an in vitro splicing assay, using a
model pre-mRNA containing IGF-I exons 4 and 5 and part of
the intervening intron. Using a series of deletion mutants,
we identified an 18-nucleotide purine-rich splicing en-
hancer in exon 5 that increases the splicing efficiency of the
upstream intron from 6 to 35%. We show that the serine-
arginine protein splicing factor-2/alternative splicing fac-
tor specifically promotes splicing in cultured cells and
in vitro and is recruited to the spliceosome in an enhancer-
specific manner. Our findings are consistent with a role for
splicing factor-2/alternative splicing factor in the regula-
tion of splicing of IGF-I alternative exon 5 via a purine-rich
exonic splicing enhancer. (Endocrinology 143: 146–154,
2002)
MOST HUMAN GENES contain introns, which must beexcised, and the exons spliced together, to allow
gene expression. A substantial number of genes make tran-
scripts that undergo alternative splicing, generating a great
number of protein isoforms (1). The regulation of alternative
splicing has been studied in some cases, and involves the
serine-arginine (SR) family of splicing proteins and several
heterogeneous nuclear RNA protein (hnRNPs) (2–4). Hu-
man IGF-I is a 70-residue peptide with growth-promoting
and metabolic actions. It is derived from a gene with six
exons, four of which are subject to alternative splicing
(Fig. 1A). The alternative splices generate different precursor
peptides, although they do not alter the structure of the
mature peptide. Exons 1 and 2 are alternative leader exons
derived from different transcription start sites, and encode
part of the signal peptide (5, 6). Exons 3 and 4 are constant.
Exons 5 and 6 are subject to a complex alternative splicing
pattern. Exon 4 usually splices to exon 6 (5), but sometimes
it splices to exon 5, representing 1–10% of IGF-I transcripts
(7). A minor isoform results from splicing of exons 4 and 5,
and from an alternative 5 splice site in exon 5 to exon 6 (8).
The production of IGF-I isoforms in several species is
regulated at transcriptional (9–11), posttranscriptional (8,
12–19) and translational (20, 21) levels. Once translated, the
variant N-terminal domains encoded by IGF-I exons 1 or 2
are processed by canine microsomes, suggesting both are
functional signal peptides (21). Alternative exons 5 and 6
encode different E domains. Part of the E domain encoded by
exon 5 contains an amidated growth-promoting peptide (22),
but there are few other functional data (23). Despite the lack
of experimental data on the functional significance of the
isoforms, there is species conservation of the genomic archi-
tecture of the exons, the splicing patterns producing alter-
native isoforms (6), and the peptide sequences (Cook, A., and
S. L. Chew, manuscript in preparation). Because alternative
splicing of exon 5 may vary depending on tissue type (13, 24,
25) or hormonal environment (8, 12–14, 17, 26), we examined
the mechanisms controlling splicing of this exon.
Materials and Methods
Construction of pre-mRNA templates
A model in vitro splicing system was established to examine splicing
between IGF-I exons 4 and 5 (Fig. 1). The entire exon 4 is 182 nucleotides
(nt), the intron is 1505 nt, and exon 5 is 218 nt (up to the most upstream
of several polyadenylation/cleavage sites). The experimental system
involved incubation of radiolabeled IGF-I pre-mRNA substrates in HeLa
nuclear extracts, followed by an assay of splicing. A major constraint of
this approach is that RNA substrates splice less efficiently and are prone
to degradation if they are too long. Therefore, for in vitro splicing ex-
periments, we used only the downstream 93 nt of exon 4 and deleted a
substantial part of the intron between exon 4 and exon 5 (Fig. 2A). This
template, called SP6-IGF4–5, was made by overlap-extension PCR with
Pfu Turbo (Stratagene, La Jolla, CA) and contains the SP6 RNA poly-
merase promoter to allow in vitro transcription of the IGF4–5 pre-
mRNA. Derivatives were made from SP6-IGF4–5 with deletions of exon
5: pre-mRNAs A, B, and C (Fig. 2A) and E, F, and G (Fig. 3A). The
derivatives were also made by PCR with Pfu Turbo. For making the
SP6-IGF4–5 template, primers SP6-E4-493S (5-ATTTAGGTGACAC-
TATAGGGCTGGAGATGTATTGCGCA) and IGF-INT4-1599A (5-
CCACCCACATGCACAAGAGAGAGA) were used to make a fragment
containing 93 bp of exon 4 and 63 bp of the upstream intron. Primers
Abbreviations: GAPDH, Glyceraldehyde phosphate dehydrogenase;
hnRNP, heterogeneous nuclear RNA protein; ICU, intensive care unit;
nt, nucleotides; SF2/ASF, splicing factor-2/alternative splicing factor;
SR, serine-arginine.
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OL-IGF-INT4-2809S (5-TGCATGTGGGTGGCTCTTCCCAGGTGAC-
CCA) and E5-557A (5-CCTTGCCTCTGTCTGTTTAAT) were used to
make a fragment containing 221 bp of the 3 end of the downstream
intron and 218 bp of exon 5. A third PCR, using SP6-E4-493S and
E5-557A, in the presence of both amplified fragments, assembled the
template. The product was cloned into pCR-blunt (Invitrogen, Carlsbad,
CA) and verified by sequencing. Templates for in vitro transcription
were made by further PCRs using a primer to the SP6 promoter and the
following downstream primers: E5-630A (5-TCCTTCTCTGAGACT-
TCG) for pre-mRNA A; E5-699A (5-CTCTGATCTGCAGACTTGCT) for
pre-mRNA B; E5-543A (5-GTTTAATCCTCCTGTCCTTCA) for pre-
mRNA C; E5-557A for pre-mRNA D; E5-648A (5-GTGTCTTTGGCCA-
ACCTT) for pre-mRNA E; E5-666A (5-TCTGTTCCCCTCCTGGAT) for
pre-mRNA F; and E5-684A (5-TTGCTTCTGTCCCCTCCT) for pre-mRNA
G. All labeled pre-mRNAs were made with SP6 RNA polymerase using
[-32P]-GTP and gel-purified. The H6 template has been described (27).
Splicing reactions
Splicing reactions were performed using 20 fmol of pre-mRNA in-
cubated at 30 C with 48% HeLa nuclear or S100 cytosolic extract, 0.5 mm
ATP, 3.2 mm MgCl2, 2.6% polyvinyl alcohol and 60 mm KCl. HeLa S100
extracts were prepared as described (28). Nuclear extracts were pur-
chased from the Computer Cell Culture Center (Mons, Belgium).
Twenty picomoles of human recombinant SF2/ASF [expressed in and
purified from Escherichia coli (29)] or SC35 (expressed in baculovirus; a
gift from R. Xu) was preincubated in the S100 extract before the comple-
mentation reaction. Intermediates and products of the splicing reactions
were phenol-extracted and run on 5.5% polyacrylamide gels before
autoradiography. Quantification was done by digital photography of the
autoradiograph with a Kodak DC210, followed by analysis with the
IMAGE program (Scion, Frederick, MD).
Immunoprecipitations
The antibody to SF2/ASF, mAb96, and control antibody to maltose-
binding protein, mAb105, have been described (30). The antibody to
hTra2 was kindly provided by Julian Venables and Ian Eperon (31).
Immunoprecipitations were performed as described (32), with some
changes. Briefly, splicing reactions were scaled up to 100 l and incu-
bated for 2 h, then diluted to 500 l with IP150 buffer (50 mm Tris-HCl,
pH 8.0; 150 mm NaCl; 0.05% NP40). Antibodies were pre-bound to
protein A-Sepharose (Fast Flow, Amersham Pharmacia Biotech, Little
Chalfont, Buckinghamshire, UK) in IP150 buffer and then added to
splicing reactions and incubated at 4 C for 1 h, before three quick washes
in IP150 buffer containing 0.5 mg/ml tRNA. The pellet was resuspended
in 10 mm Tris-Cl pH 8.0 and 0.1 mm EDTA, and immunoprecipitated
RNA recovered by phenol extraction and ethanol precipitation. The
supernatant from the anti-MBP tubes was ethanol precipitated, and 10%
of the resuspended material was loaded as a control.
Cotransfections and RNA analyses
An IGF-I minigene containing exons 4, 5, and 6 (pEGFP-IGF-F1) was
made. A PCR fragment containing exon 4 (171 bp), intron 4 (1505 bp), exon
5 up to the first polyadenylation/cleavage site (218 bp) and the 5 end of
intron 5 (198 bp) was made with primers EcoRI-MOD4-2244S (5-GGAAT-
TCCGGGTATGGCTCCAGCAGT) and NotI-MODINT3238A (5-ATAA-
GAATGCGGCCGCACATATATTGACATAGGCAATTCT) using Expand
High Fidelity polymerase (Roche Molecular Biochemicals, Mannheim,
Germany) to amplify human genomic DNA. A second PCR fragment
containing the 3 end of intron 5 (284 bp) and exon 6 (399 bp) was made
with primers NotI-MODINT3367S (5-ATAAGAATGCGGCCGCATA-
GAAGCAGATGAATCAACT) and SacII-MOD6A (5-GCTGAGC-
CGCGGAGTGCAACTGGATCTATACAA). The fragments were as-
sembled via the NotI sites and cloned into the EcoRI and SacII sites of
pEGFP-C1 (CLONTECH Laboratories, Inc., Palo Alto, CA). The con-
struction was verified by sequencing on both strands and was used as
FIG. 1. Alternative splicing of the human IGF-I pre-mRNA. Exons
are shown as boxes, introns as lines, transcription start sites as ar-
rows, splicing patterns as sloped lines, and polyadenylation signals as
the letter A. The protein-coding potential of the exons is indicated
underneath.
FIG. 2. In vitro splicing of IGF-I minigene transcripts with progres-
sive deletions of exon 5. A, Diagrams of the pre-mRNAs used in in vitro
splicing experiments. The splicing substrate IGF4–5 is shown, exon
4 as an open box, the intron as a line and exon 5 as a black box. The
deletion of 1221 nt from the intron is represented as double diagonal
lines. The sizes in nucleotides (nt) are marked above the diagram. The
deletion mutants, A, B, and C of exon 5 are shown underneath. The
length of the 3 exon is given after each deletion. B, Splicing reactions
using IGF4–5 pre-mRNAs. The radiolabeled pre-mRNA substrates
represented in Fig. 2A (and as indicated by letters above the lanes)
were incubated in HeLa nuclear extracts for 1 or 2 h (as shown above
the lanes). The reactions were deproteinized, RNA extracted and run
on denaturing polyacrylamide gels. The identity of the pre-mRNA,
intron-lariat, and mRNA bands is indicated by symbols on the right
of the autoradiograph, with the mRNAs also indicated by the square
bracket.
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a reporter in cotransfection experiments (33) with plasmids pCG-SF2
(expressing SF2/ASF) or pCG-SC35 (expressing SC35). Briefly, 2 g of
pEGFP-IGF-F1, with or without 2 g of pCG-SF2 or pCG-SC35, was
transfected into approximately 75% confluent HeLa cells plated in 3-cm
diameter wells using Fugene 6 (Roche Molecular Biochemicals), accord-
ing to the manufacturer’s protocol. Total RNA was harvested 24 h later
using the TRI reagent (Sigma, St. Louis, MO), and RT-PCR was per-
formed as described (8). Splicing to exon 5 was assayed with primers
EGFP-1323S (5-GTACAAGTCCGGACTCAGAT) and E5-557A (5-
CCTTGCCTCTGTCTGTTTAAT). Splicing to exon 6 was assayed with
primers EGFP-1323S and E6-669A (5-CTGCGGTGGCATGTCAC-
TCTT). Reaction products were resolved on 6% nondenaturing poly-
acrylamide gels, photographed and scanned with a Scanjet 5370C
(Hewlett-Packard Co., Palo Alto, CA) and quantified through the
IMAGE program. Muscle biopsies were obtained from patients after
written informed consent or assent and approval of the study by the local
research ethics committee and were subjected to RNA extraction, RT-
PCR, Southern blotting and quantification, as described (8). Serum IGF-I
was assayed by an in-house RIA (normal range 108–369 ng/ml; inter-
assay and intraassay coefficient of variation 10%).
Results
Splicing of IGF-I exon 5 in vitro
We first constructed an IGF-I splicing substrate consisting
of exons 4 and 5 and the entire intervening intron. This
pre-mRNA was very unstable under standard in vitro splic-
ing conditions (data not shown). We therefore made another
IGF-I pre-mRNA substrate with a 1221-bp deletion in the
intron, IGF4–5 (Fig. 2A). The construct was made by overlap
extension PCR. The size and position of the deletion was
designed to allow sufficient intronic sequence so that dis-
ruption of the splice sites was unlikely, but not too much to
make the pre-mRNA difficult to manipulate or subject to
degradation. In particular, the branchsite of the intron has
not been mapped, so a longer section at the 3 end of the
intron was retained. This substrate spliced in vitro with little
degradation (Fig. 2B, lane 9). We then generated a deletion
series from the 3 end of exon 5 (Fig. 2A). The initial deletions
were large and designed to examine regions of exon 5 for
elements affecting splicing efficiency. An increase in splicing
efficiency between pre-mRNAs A and B was observed (Fig.
2B, compare lanes 2 and 3 with lanes 4 and 5). Substrates C
and D gave clear spliced products at 2 h (lanes 7 and 9), but
the kinetics of mRNA appearance was slower than B at 1 h
(compare lanes 6 and 8 to lane 4).
To define elements within the 69-nt segment between A
and B, this region was subdivided into three segments (E, F,
and G; Fig. 3A). A significant improvement in splicing effi-
ciency was seen between E and F pre-mRNAs (compare lanes
4 and 6; Fig. 3B), but not between A and E pre-mRNAs
(compare lanes 2 and 4, Fig. 3B). In three independent ex-
periments, the mean ratio of mRNA to pre-mRNA after 1 and
2 h of splicing increased from 3% (se 0.5%) and 6% (se 1%)
for pre-mRNAs A and E to 35% (se 5%) for pre-mRNA F (Fig.
3C) (P  0.02, Kruskal-Wallis test). The sequence between
pre-mRNA E and F is 18-nt long and purine-rich (ATCCAG-
GAGGGGAACAGA) and begins 64 nt downstream of the 3
splice site of exon 5 and 15 nt downstream of the alternative
5 splice site in exon 5. Further enhancement of splicing was
not achieved by sequences downstream of this element, and
some delay in the kinetics of the reactions was seen with
pre-mRNAs C, D, and G, suggesting the presence of silencer
elements.
FIG. 3. Fine deletion mapping of the exon 5 enhancer by in vitro splic-
ing. A, Diagram of finer deletions of IGF4–5, pre-mRNAs E, F, and G,
is shown, with sizes of the 3 exons indicated in nucleotides at the end
of the exon. B, Splicing reactions were performed by incubating the
pre-mRNAs in nuclear extracts and products run on gels The pre-
mRNAs used and times of incubation are shown above the lanes. The
identity of the pre-mRNA and mRNA bands is indicated by the symbols
on the right of the gel, with mRNAs also indicated by a square bracket.
C, Quantification of splicing efficiencies. The y-axis shows the ratio of
mRNA to pre-mRNA expressed as a percentage; the x-axis indicates the
identity of the pre-mRNAs; error bars represent SE (n  3).
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SF2/ASF promotes splicing of IGF-I exon 5
Several SR proteins in mammalian (34) and Drosophila (35)
nuclear extracts bind purine-rich exonic elements to promote
splicing. S100 cytosolic extracts were used to identify trans-
acting factors required for promotion of splicing to exon 5.
These extracts are not competent for splicing because they
lack SR proteins (36). We complemented S100 extracts with
either of two recombinant SR proteins: SF2/ASF and SC35.
Both SF2/ASF and SC35 were able to restore splicing of a
-globin pre-mRNA in an S100 extract (Fig. 4, lanes 3 and 4).
We exploited this system to study the specificity of action of
SR proteins on IGF pre-mRNA in vitro splicing. We incubated
pre-mRNAs A, E, and F in nuclear and S100 extracts. As
before, pre-mRNAs A and E showed only traces of splicing
in nuclear extract (lanes 5 and 9), whereas pre-mRNA F was
efficiently spliced (lane 13). None of the pre-mRNAs spliced
in the S100 extract alone (lanes 2, 10, and 14; nonspecific
degradation of the pre-mRNA is seen in lane 6). However,
pre-mRNA F spliced efficiently in an S100 extract comple-
mented with SF2/ASF (lane 15), but not in an S100 extract
complemented with SC35 (lane 16). This indicated a specific
requirement for SF2/ASF and the purine-rich enhancer for in
vitro splicing to IGF-I exon 5 and ruled out a nonspecific effect
of exon length on splicing of the pre-mRNAs. SF2/ASF was
unable to promote splicing of the IGF4–5 pre-mRNA in the
absence of this enhancer (lane 11). This experiment was in-
dependently performed twice with similar results.
SF2/ASF is recruited to the IGF-I pre-mRNA spliceosome
in an enhancer-specific manner
Tra2 is a Drosophila SR protein that regulates alternative
splicing of Doublesex pre-mRNA via binding to nonpurine-
rich repeat elements and a purine-rich enhancer in Drosophila
nuclear extracts and also when added to mammalian nuclear
extracts. Drosophila Tra2 binds the exonic enhancers in a
cooperative manner with SR proteins, including SF2/ASF
(35). hTra2 (37) and hTra2 (38) are human homologs of
Tra2 and also promote sequence-specific splicing in mam-
malian pre-mRNA (39). To test whether similar cooperation
may take place for the IGF-I enhancer, we assayed for the
presence of SF2/ASF and hTra2 in the spliceosome by im-
munoprecipitations with anti-SF2/ASF and anti-hTra2.
First, pre-mRNAs E and F were incubated in nuclear extracts
for 2 h. Next, specific antibodies were added to the reactions
and immunoprecipitations were performed using protein
A-Sepharose. If SF2/ASF or hTra2 are present in spliceo-
somes assembling on IGF pre-mRNAs, then spliceosomes
and labeled pre-mRNA should be coimmunoprecipitated.
The pellets containing labeled RNAs were deproteinized and
the RNA run on polyacrylamide gels and visualized by au-
toradiography. The results showed that enhancer-containing
pre-mRNA F and mRNA were immunoprecipitated with
anti-SF2/ASF or anti-hTra2 (Fig. 5, lanes 7 and 8), whereas
only background levels were obtained with the control anti-
MBP antibody (lane 6). By contrast, in the absence of the
enhancer, pre-mRNA E was immunoprecipitated at back-
ground levels only by anti-SF2/ASF (lane 3). Antibodies to
hTra2 immunoprecipitated pre-mRNA E (i.e. in the absence
of the enhancer) at levels higher than background (lane 4; and
on overexposed blots, data not shown). This experiment was
performed independently four times with similar results. We
conclude that hTra2 is present in the IGF-I spliceosome, but
not in an enhancer-dependent manner and it is unlikely that
a cooperative interaction between SF2/ASF and hTra2 oc-
curs at the IGF-I enhancer.
FIG. 4. S100-complementation reactions with
IGF4–5 substrates. Pre-mRNAs A, E, and F were
incubated for 2 h in either nuclear extract (NE), or
S100 extract (S100). Some S100 reactions were com-
plemented with SR proteins SF2/ASF (SF2) or SC35.
The extracts and SR proteins used in each reaction
are indicated by  signs above the lanes. -globin
pre-mRNA (H6) was used as a control in lanes 1–4.
The pre-mRNAs used are indicated above the
lanes. The identity of the IGF pre-mRNA, lariat-
intermediate, lariat-product and mRNA bands are
given on the right of the autoradiograph, with the
mRNA bands also shown as a square bracket. The
identity of the -globin pre-mRNA, mRNA and 5
exon intermediate bands is given on the left of the
autoradiograph.
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Overexpression of SF2/ASF in cultured cells promotes
inclusion of exon 5
To this point, experiments had been performed in vitro in
a cell-free system. To show that regulation of splicing to IGF-I
exon 5 was regulated by SF2/ASF in living cells, cotrans-
fection experiments in cultured HeLa cells were performed.
We designed and constructed an IGF-I minigene, pEGFP-
IGF-F1, in a eukaryotic expression plasmid. Note that this
minigene was not subject to the same size limitations as the
templates used for in vitro splicing and contained the entire
intron between exons 4 and 5, and well as exon 6 and parts
of the intron between exons 5 and 6. HeLa cells were trans-
fected with pEGFP-IGF-F1 with or without cotransfection
with plasmids expressing SF2/ASF (pCG-SF2) or SC35
(pCG-SC35). Splicing via exon 5 was very low in cells ex-
pressing the IGF-I minigene alone (Fig. 6A, lane 7), whereas
splicing via exon 6 was clearly detected (lane 11). When
SF2/ASF was over-expressed, splicing via exon 5 inclusion
was promoted (lane 8), with a mean change of 4.7-fold over
three separate experiments (P 0.004, two-tailed t test) (Fig.
6B). Overexpression of SC35 also promoted exon 5 inclusion,
but less so (mean change of 3.6-fold; P  0.03). In vitro, SC35
did not promote splicing to exon 5 via the purine-rich se-
quence in pre-mRNA F (Fig. 4). Therefore, it is likely that the
results in cultured cells reflect the additional exon 5 and
downstream intronic sequences present in the minigene (not
present in pre-mRNA F) and the presence of SC35-dependent
enhancers in the additional sequences.
Regulation of exon 5 inclusion in human muscle
To investigate whether disordered expression of IGF-I
may be implicated in clinical situations associated with mus-
cle abnormalities, we examined the regulation of the IGF-I
isoforms at the mRNA level in muscle biopsies available
from studies of 20 patients. Ten patients had GH deficiency
and muscle biopsies were performed at baseline, and re-
peated 6 months after GH treatment (n  5 patients) or
placebo treatment (n  5 patients). Ten other patients were
treated in an intensive care unit and had muscle biopsies at
baseline and repeated 4 and 8 d later, as part of a study of
intensive care unit (ICU)-related myopathy. IGF-I mRNAs
containing exon 5 or 6 were measured by semiquantitative
duplex RT-PCR using a glyceraldehyde phosphate dehydro-
genase (GAPDH) PCR product as a standard.
In the group of patients with GH deficiency, GH-treated
patients had increased relative IGF-I exon 5 levels (for rep-
resentative data, see Fig. 7A, compare lane 1 with lane 2 and
FIG. 5. Immunoprecipitation of labeled IGF-I transcripts from splic-
ing reactions. Pre-mRNAs without (E) or with (F) the exon 5 enhancer
element were incubated under splicing conditions. Prespliceosomal
and spliceosomal complexes were immunoprecipitated with the in-
dicated antibodies, and the labeled RNAs extracted from the precip-
itates. The lanes labeled SUP were loaded with 1/10 of the RNA
recovered from the supernatant of the control anti-MBP immunopre-
cipitations. The pre-mRNAs and antibodies used are indicated above
the lanes. The identity of the pre-mRNA and mRNA bands is shown
by symbols on the right of the gel.
FIG. 6. Effect of transient overexpression of SF2/ASF or SC35 on
alternative splicing of a cotransfected IGF-I minigene. A, The left
panel shows total RNA from each well, as a control for recovery and
loading. M, lambda/BstEII markers. The right panel shows repre-
sentative data from an RT-PCR experiment. The exon amplified by
each PCR reaction is indicated above the lanes. The  symbol above
each lane indicates the plasmids used in transfections. M, pBR322/
MspI markers. B, Summary of data from three experiments showing
the fold change of the ratio of exon 5 to exon 6 expression compared
with the IGF-I minigene alone. Error bars represent SD.
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lane 3 with lane 4). Placebo-treated patients showed less
marked changes in IGF-I exon 5 levels (lanes 6–11). As a
group, GH-treated patients had a significant 10.0-fold in-
crease (se 2.9-fold) in relative inclusion of IGF-I exon 5 com-
pared with baseline, compared with a 2.5-fold increase in the
placebo-treated patients (se 1.1-fold) (Fig. 7B, solid bars; P 
0.032; two-tailed t test). Note that one patient in the GH-
treated group, who showed no response by any criteria (in-
cluding the serum IGF-I level, which failed to rise into the
normal range) and who had a drop in muscle IGF-I exon 5
levels, was excluded from all analyses because we question
the compliance of the patient with GH treatment. At baseline,
there was no difference in age or body mass index between
the GH-treated and the placebo-treated group (mean age 45
compared with 43.6 yr; mean body mass index 30 compared
with 30.6 kg/m2). The GH-treated group were all male,
whereas two of the five placebo-treated group were male.
The increase in serum IGF-I levels after 6 months was sig-
nificantly greater in the GH-treated compared with the
placebo-treated group (mean rise in serum IGF-I of 441 vs.
45.4 ng/ml; P  0.0003; two-tailed t test).
The patients in intensive care were heterogeneous with
seven admitted after coronary or vascular surgery and three
suffering severe sepsis. Four patients (including the three
suffering sepsis) had clinical, electrophysiological, and his-
tological evidence of myopathy. Five patients without clin-
ical evidence of myopathy nevertheless had a drop in serum
IGF-I levels to below the normal range from a mean of 138.2
ng/ml falling to a mean of 85 ng/ml (P  0.018; two-tailed
paired t test) by the time of the second biopsy. For one
patient, no biochemical, electrophysiological, or histological
data were available. In all the intensive care patients, the
IGF-I mRNA expression patterns were unchanged (Fig. 7B).
IGF-I exon 6-containing transcript levels were similar in all
groups (Fig. 7B, open bars).
Discussion
A purine-rich exonic splicing enhancer in IGF-I exon 5 was
identified by in vitro splicing assays with pre-mRNAs har-
boring systematic deletions in exon 5. This enhancer func-
tioned specifically with SF2/ASF, and overexpression of
SF2/ASF in cultured HeLa cells promoted splicing via exon
5 inclusion. Splicing enhancer sequences have been identi-
fied in several regulated and constitutive exons, and may be
classified into purine rich (40) and nonpurine rich (41). En-
hancers interact with SR proteins, including SF2/ASF (35,
42–48). SF2/ASF has high binding affinity for certain purine-
rich sequences in vitro (49) and, under splicing conditions,
SF2/ASF and SC35 function through distinct and degenerate
consensus sequences (50–52). We analyzed IGF-I exon 5 us-
ing matrices for predicting sequences through which SF2/
ASF and SC35 function (50, 52). The 18-nt extension between
pre-mRNAs E and F significantly increases splicing to exon
5. The extended sequence in the F pre-mRNA completes an
SF2/ASF high-score heptamer motif (beginning at nt 60;
Fig. 8) and adds yet another (beginning at nt 69). For SC35,
the extension does not affect the number of high-score motifs
present. The matrices show two high-score motifs for SF2/
ASF (beginning at nt 25 and 37) and two for SC35 (begin-
ning at nt 5 and 53) in the part of exon 5 included in pre-
FIG. 7. A, IGF-I exon 5 inclusion in muscle biopsies from GH-defi-
cient patients. Representative semiquantitative RT-PCR data for
IGF-I exon 5 inclusion in muscle biopsies from GH-treated vs. placebo-
treated patients are shown in the top panel. GAPDH RT-PCR prod-
ucts were measured as an internal control, bottom panel. B, Relative
level of IGF-I RT-PCR products from GH-deficient and ICU patients
in follow-up muscle biopsies compared with baseline. The data are
corrected for GAPDH expression and expressed as fold change from
the baseline biopsy level. Solid bars show exon 5-containing products;
open bars show exon 6-containing products; error bars are SE; GH,
GH-treated; no GH, placebo-treated; ICU2, second biopsy from in-
tensive-care patients; ICU3, third biopsy from intensive-care patients.
FIG. 8. High-score matches to SF2/ASF and SC35 consensus motifs
in IGF-I exon 5. The nucleotides of exon 5 are given on the x-axis and
the score is on the y-axis. SF2/ASF scores are in black bars and SC35
in gray bars. The sequence extension in pre-mRNA F is shown in bold.
Only motifs with scores above the previously defined thresholds of
1.956 for SF2/ASF and 2.383 for SC35 are shown (77).
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mRNA A. However, a score above threshold may not be
sufficient for exonic splicing enhancer function, because of
the surrounding context, e.g. a juxtaposed silencer, which we
are currently unable to predict (52). Our data are compatible
with IGF-I exon 5 being a substrate for SF2/ASF via a short
enhancer element, and thus, this mechanism may underlie
the control of splicing to this exon.
Another feature of the IGF-I exon 5 sequence is the pres-
ence of an alternative 5 splice site contained in the last 18 nt
of pre-mRNA E. This site is used rarely in a tissue-specific
manner in human liver (8) and is used in a human kidney
tumor library (GenBank accession no. AI478804), although
an equivalent site is commonly used in rodents and rabbits
(12, 13, 17). The presence of this site did not promote in vitro
splicing to exon 5, nor was the site used for splicing when an
IGF-I minigene was transfected into cultured HeLa cells.
These data suggest that this site does not interact with U1
snRNP in HeLa extracts or cultured cells, perhaps due to the
lack of a specific splicing activator or presence of an inhib-
itory factor, although the experiments reported here do not
address this question.
We attempted to understand the regulation of IGF-I al-
ternative splicing by examining human muscle biopsies
taken during studies in patients with GH deficiency. There
was a significant increase in the ratio of exon 5-containing
mRNAs in patients after treatment with GH, but not in those
treated with placebo. The consequence of changes in splicing
to exon 5 or 6 involves the E domain of the IGF-I precursor.
The physiological roles of the E domains are unknown, al-
though they are not present in insulin. The E domain en-
coded by exon 5 has been shown to harbor a mitogenic
peptide fragment (22). Our preliminary experiments suggest
the E domains may target the IGF-I precursor peptide to
different cellular fates (unpublished data).
We also examined muscle biopsies from a heterogeneous
group of intensive care patients, either with electrophysio-
logical and histological evidence of myopathy, or with falls
of serum IGF-I levels to below the normal range. GH resis-
tance has been observed in such patients (53). In the intensive
care patients, there was no trend evident in the ratios of
muscle IGF-I mRNA isoforms. Our data make it less likely
that changes in muscle IGF-I production play a role in ICU
myopathy or in the falling IGF-I levels seen in these patients
(53). It is possible that the fall in serum IGF-I in our patients
was due to reduced liver production, as has been shown
in rodent models (see references cited in 53) and by liver-
specific IGF-I deletions in mice (54).
Several studies have investigated alternative splicing in
the context of skeletal muscle differentiation, and in most
cases this regulated expression involves exons that undergo
skeletal muscle-specific inclusion or exclusion (e.g. in tropo-
myosin or troponin pre-mRNAs). Some of the factors regu-
lating such exons are CUG-binding protein (55), SF2/ASF
(56), and hnRNP H (57). The main difference between the
skeletal muscle differentiation alternative splicing systems
and our experiments is that muscle biopsies from the patients
presumably represent fully differentiated tissue. Fully dif-
ferentiated tissue may have a more limited capacity for
changing splicing compared with that occurring during mus-
cle differentiation. Also, both IGF-I isoforms are expressed,
albeit with varying relative abundance. Thus, the effect of
GH in changing IGF-I pre-mRNA splicing in differentiated
adult skeletal muscle is quantitative. How the spliceosome is
adapted to give qualitative changes in exon selection during
muscle differentiation as well as quantitative changes seen in
fully differentiated muscle is unclear.
SF2/ASF binding promotes assembly of the splicing ma-
chinery (34) and later stages of the splicing reaction (58–61).
In a well characterized system of alternative splicing, SF2/
ASF binds to the Drosophila doublesex purine-rich enhancer in
a cooperative manner with Tra2 (35). hTra2 is one of two
human homologs of Tra2 (37, 38) and promotes splicing in
a sequence-specific manner (39). hTra2 binds a natural ex-
onic splicing enhancer in a human s tropomyosin alterna-
tive exon (Eperon, I. C., personal communication). In our
experiments, hTra2 was present in the IGF-I spliceosome,
but not in an enhancer-dependent manner. By contrast, SF2/
ASF associated with the spliceosome in an enhancer-depen-
dent manner. This observation argues against simultaneous
cooperative binding by SF2/ASF and hTra2 in the context
of the IGF-I exon 5 enhancer but does not exclude the pos-
sibility that pre-bound hTra2 facilitates the recruitment of
SF2/ASF, or that SF2/ASF binds cooperatively with other SR
proteins or other RNA-binding proteins.
The activity of SF2/ASF may be regulated by several
mechanisms (34, 62), including phosphorylation by kinases
(63), cellular localization (64), and varying tissue concentra-
tions (30). Some studies implicate SR proteins in signaling-
mediated changes in alternative splicing. Insulin signaling
changes splicing involving rat fibronectin exon EIIIB and is
associated with increased levels of HRS, the rat homolog of
SRp40 (48). The alternative splicing response to serum stim-
ulation or withdrawal in the mouse SRp20 pre-mRNA in-
volves SF2/ASF and SRp20 (65, 66). Alternative splicing of
CD44 and CD45 pre-mRNAs occurs during cytokine-
induced T-cell differentiation, via PKC and Ras pathways
(67–69). SC35, SF2/ASF and other SR proteins alter CD44
and CD45 splicing (70–72).
It is possible that SF2/ASF and the purine-rich enhancer
are involved in pathways that control the relative levels of
expression of IGF-I isoforms in different tissues (13, 24, 25)
and in response to GH in animal or cell culture models (8,
12–14, 17, 26), with some exceptions (73, 74). In vitro models
for regulated splicing systems are difficult to develop (75),
and hence it has not been possible to test whether SF2/ASF
and the enhancer function in hormonally regulated or tissue-
dependent alternative splicing of IGF-I. However, there are
examples of enhancers in other exons with dual function in
promoting splicing both in constitutive and regulated con-
texts (69, 76). Our working hypothesis, derived from the
present work in HeLa cells, is that alterations in the local-
ization, phosphorylation or level of SF2/ASF by cellular sig-
nals, such as GH-stimulated pathways, may control IGF-I
exon 5 inclusion via interaction with the purine-rich exonic
element.
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